Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ontology highlight
ABSTRACT: RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.
DISEASE(S): Ovarian Tumor,Acute Myeloid And Lymphoid Leukemias,Leukemia, Lymphoid,Brain Tumor,Colorectal Cancer,Liver Cancer,Pancreatic Cancer,Ovarian Neoplasms,Breast Cancer
PROVIDER: 2197463 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA